2016
C. Ma et al. / Journal of Organometallic Chemistry 691 (2006) 2014–2022
2.2.1. Me3Sn(C5H4N2OS)SnMe3 (1)
2.2.4. Me3Sn(C4H2N2OS)SnMe3 (4)
Complex 1 was synthesized by adding 4-hydroxy-2-
mercapto-6-methylpyrimidine (0.142 g, 1 mmol), sodium
ethoxide (0.136 g, 2 mmol) and trimethyltin chloride
(0.398 g, 2 mmol) to the solution of methanol.
Complex 4 was synthesized by the same procedure as 1
with 4-hydroxy-2-mercapto-pyrimidine (0.128 g, 1 mmol),
sodium ethoxide (0.136 g, 2 mmol) and trimethyltin chlo-
ride (0.398 g, 2 mmol).
m.p. 116–118 °C. Yield, 0.374 g, 80%. Anal. Calc. for
C11H22N2OSSn2: C, 28.24; H, 4.74; N, 5.99. Found: C,
28.27; H, 4.71; N, 6.01%. IR (KBr, cmÀ1): 1583 (C@N),
560 (Sn–C), 458 (Sn–N), 307 (Sn–S), 467 (Sn–O). 1H
m.p. 119–122 °C. Yield, 0.354 g, 78%. Anal. Calc. for
C10H20N2OSSn2: C, 26.47; H, 4.44; N, 6.17. Found: C,
26.49; H, 4.41; N, 6.18%. IR (KBr, cmÀ1): 1582 (C@N),
565 (Sn–C), 459 (Sn–N), 306 (Sn–S), 469 (Sn–O). 1H
2
2
NMR (CDCl3): d 0.90 (s, JSn,H = 68.6 Hz, 18H), 1.34 (s,
NMR (CDCl3): d 0.90 (s, JSn,H = 68.8 Hz, 18H), 7.48 (s,
ring-CH3, 3H), 7.44 (s, ring-C5-H, 1H). 13C NMR
(CDCl3): d 8.2, 10.6 (Sn–CH3), 24.7 (ring-CH3), 172.4
(C2), 179.1 (C4), 132.1 (C5), 164.4 (C6). 119Sn NMR
(CDCl3): À135, À95 ppm. MS (m/z, ion, intensity): (470)
[Me3Sn(C5H4N2OS)SnMe3]+ M+ (2), (455) [Me3Sn(C5H4-
N2OS)SnMe2]+ (45), (305) [Me3Sn(C5H4N2OS)]+ (100),
(165) [Me3Sn]+ (80), (120) [Sn]+ (5).
ring-C5–H, 1H), 8.80 (s, ring-C6–H, 1H). 13C NMR
(CDCl3): d 8.12, 10.5 (Sn–CH3), 172.4 (C2), 179.1 (C4),
132.1 (C5), 157.2 (C6). 119Sn NMR (CDCl3): À137,
À95 ppm. MS (m/z, ion, intensity): (456) [Me3Sn(C4H2-
N2OS)SnMe3]+ M+ (2), (441) [Me3Sn(C4H2N2OS)SnMe2]+
(45), (291) [Me3Sn(C4H2N2OS)]+ (100), (165) [Me3Sn]+
(80), (120) [Sn]+ (5).
2.2.2. Ph3Sn(C5H4N2OS)SnPh3 (2)
2.2.5. Ph3Sn(C4H2N2OS)SnPh3 (5)
Complex 2 was synthesized by the same procedure as 1
with 4-hydroxy-2-mercapto-6-methylpyrimidine (0.142 g,
1 mmol), sodium ethoxide (0.136 g, 2 mmol) and triphenyl-
tin chloride (0.770 g, 2 mmol).
Complex 5 was synthesized by the same procedure as 1
with 4-hydroxy-2-mercapto-pyrimidine (0.128 g, 1 mmol),
sodium ethoxide (0.136 g, 2 mmol) and triphenyltin chlo-
ride (0.770 g, 2 mmol).
m.p. 185–187 °C. Yield, 0.672 g, 76%. Anal. Calc. for
C41H34N2OSSn2: C, 58.61; H, 4.08; N, 3.33. Found: C,
58.56; H, 4.11; N, 3.35%. IR (KBr, cmÀ1): 1576 (C@N),
560 (Sn–C), 467 (Sn–N), 311 (Sn–S), 469 (Sn–O). 1H
NMR (CDCl3): d 7.36–7.81 (m, Sn–C6H5, 30H), 1.33 (s,
ring-CH3, 3H), 7.45 (s, ring-C5–H, 1H). 13C NMR
(CDCl3): d 24.7 (ring-CH3), 172.5 (C2), 179.2 (C4), 132.5
(C5), 164.4 (C6), 137.5 (o-C), 128.8 (m-C), 129.3 (p-C),
142.6 (i-C). 119Sn NMR (CDCl3): À173, À135 ppm. MS
(m/z, ion, intensity): (842) [Ph3Sn(C5H4N2OS)SnPh3]+
M+ (2), (765) [Ph3Sn(C5H4N2OS)SnPh2]+ (45), (491)
[Ph3Sn(C5H4N2OS)]+ (100), (351) [Ph3Sn]+ (80), (120)
[Sn]+ (5).
m.p. 183–185 °C. Yield, 0.644 g, 78%. Anal. Calc. for
C40H32N2OSSn2: C, 58.15; H, 3.90; N, 3.39. Found: C,
58.10; H, 3.91; N, 3.35%. IR (KBr, cmÀ1): 1578 (C@N),
556 (Sn–C), 469 (Sn–N), 309 (Sn–S), 468 (Sn–O). 1H
NMR (CDCl3): d 7.36–7.79 (m, Sn–C6H5, 30H), 7.49 (s,
ring-C5-H, 1H), 8.81 (s, ring-C6–H, 1H). 13C NMR
(CDCl3): d 172.5 (C2), 179.2 (C4), 132.5 (C5), 157.3 (C6),
137.5 (o-C), 128.8 (m-C), 129.3 (p-C), 142.6 (i-C).
119Sn NMR (CDCl3): À171, À133 ppm. MS (m/z, ion,
intensity): (828) [Ph3Sn(C4H2N2OS)SnPh3]+ M+ (2),
(757) [Ph3Sn(C4H2N2OS)SnPh2]+ (45), (477) [Ph3Sn-
(C4H2N2OS)]+ (100), (351) [Ph3Sn]+ (80), (120) [Sn]+
(5).
2.2.3. (PhCH2)3Sn(C5H4N2OS)Sn(CH2Ph)3 (3)
Complex 3 was synthesized by the same procedure as 1
with 4-hydroxy-2-mercapto-6-methylpyrimidine (0.142 g,
1 mmol), sodium ethoxide (0.136 g, 2 mmol) and tribenzyl-
tin chloride (0.854 g, 2 mmol).
2.2.6. (PhCH2)3Sn(C4H2N2OS)Sn(CH2Ph)3 (6)
Complex 6 was synthesized by the same procedure as 1
with 4-hydroxy-2-mercapto-pyrimidine (0.128 g, 1 mmol),
sodium ethoxide (0.136 g, 2 mmol) and tribenzyltin chlo-
ride (0.854 g, 2 mmol).
m.p. 125–127 °C. Yield, 0.703 g, 76%. Anal. Calc. for
C47H46N2OSSn2: C, 61.07; H, 5.02; N, 3.03. Found: C,
61.04; H, 4.98; N, 3.07%. IR (KBr, cmÀ1): 1581 (C@N),
557 (Sn–C), 456 (Sn–N), 309 (Sn–S), 467 (Sn–O). 1H
NMR (CDCl3): d 7.46–7.79 (m, Sn–CH2–C6H5, 30H),
3.26 (s, CH2, 12H), 1.35 (s, ring-CH3, 3H), 7.43 (s, ring-
C5–H, 1H). 13C NMR (CDCl3): d 24.7 (ring-CH3), 172.4
(C2), 179.1 (C4), 132.1 (C5), 163.4 (C6), 23.6, 21.9 (s,
CH2), 127.3 (o-C), 127.4 (m-C), 128.2 (p-C), 124.2 (i-C).
119Sn NMR (CDCl3): À151, À101 ppm. MS (m/z, ion,
intensity): (926) [(PhCH2)3Sn(C5H4N2OS)Sn(CH2Ph)3]+
M+ (2), (835) [(PhCH2)3Sn(C5H4N2OS)Sn(CH2Ph)2]+ (45),
(533) [(PhCH2)3Sn(C5H4N2OS)]+ (100), (393) [(PhCH2)3-
Sn]+ (80), (120) [Sn]+ (5).
m.p. 123–125 °C. Yield, 0.692 g, 76%. Anal. Calc. for
C46H44N2OSSn2: C, 60.69; H, 4.87; N, 3.08. Found: C,
60.72; H, 4.88; N, 3.07%. IR (KBr, cmÀ1): 1581 (C@N),
559 (Sn–C), 458 (Sn–N), 306 (Sn–S), 464 (Sn–O). 1H NMR
(CDCl3): d 7.46–7.79 (m, Sn–CH2–C6H5, 30H), 3.25 (s,
CH2, 12H), 7.47 (s, ring-C5–H, 1H), 8.82 (s, ring-C6–H,
1H). 13C NMR (CDCl3): d 172.4 (C2), 179.1 (C4), 132.1
(C5), 157.3 (C6), 23.6, 21.9 (s, CH2), 127.3 (o-C), 127.4
(m-C), 128.2 (p-C), 124.2 (i-C). 119Sn NMR (CDCl3):
À158, À102 ppm. MS (m/z, ion, intensity): (912) [(PhCH2)3-
Sn(C4H2N2OS)Sn(CH2Ph)3]+ M+ (2), (821) [(PhCH2)3-
Sn(C4H2N2OS)Sn(CH2Ph)2]+ (45), (519) [(PhCH2)3Sn-
(C4H2N2OS)]+ (100), (393) [(PhCH2)3Sn]+ (80), (120) [Sn]+
(5).